Zamarin, Dmitriy

Publications

Sort by

Co-Author Network

selected publications

Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 3
Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer. Cancer discovery. 2022 Academic Article GET IT
Times cited: 9
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2022 Academic Article GET IT
Times cited: 1
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. Nature cancer. 2022 Academic Article GET IT
Times cited: 18
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature. 2022 Article GET IT
Times cited: 1
Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix. The Journal of pathology. 2022 Academic Article GET IT
Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature. 2022 Academic Article GET IT
Times cited: 8
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. Journal for immunotherapy of cancer. 2022 Academic Article GET IT
Times cited: 11
Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. Gynecologic oncology. 2022 Academic Article GET IT
Times cited: 5
Beyond T Cells: IgA Incites Immune Recognition in Endometrial Cancer. Cancer research. 2022 Editorial Article GET IT
Times cited: 1
Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. Cancer research. 2022 Academic Article GET IT
Times cited: 3
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022 Academic Article GET IT
Times cited: 86
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2022 Academic Article GET IT
Times cited: 19
Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors. NPJ genomic medicine. 2021 Academic Article GET IT
Times cited: 150
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. Gynecologic oncology. 2021 Academic Article GET IT
Times cited: 1
Rejuvenating dysfunctional T cells in ovarian cancer: CD28 is the license to kill. Cancer cell. 2021 Comment GET IT
Pattern of disease and response to pembrolizumab in recurrent cervical cancer. Gynecologic oncology reports. 2021 Academic Article GET IT
Times cited: 2
Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. Journal of the National Cancer Institute. 2021 Academic Article GET IT
Times cited: 7
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021 Academic Article GET IT
Times cited: 69
Tim-4⁺ cavity-resident macrophages impair anti-tumor CD8⁺ T cell immunity. Cancer cell. 2021 Academic Article GET IT
Times cited: 61
Standardized Uptake Value Illuminates Tumor Inflammation and Treatment Response. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Comment GET IT
Tumor Immunity and Immunotherapy for HPV-Related Cancers. Cancer discovery. 2021 Review GET IT
Times cited: 38
Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. Gynecologic oncology. 2021 Academic Article GET IT
Times cited: 4
Expanding Our Impact in Cervical Cancer Treatment: Novel Immunotherapies, Radiation Innovations, and Consideration of Rare Histologies. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2021 Review GET IT
Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. Cancer. 2021 Review GET IT
Times cited: 23
Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. Gynecologic oncology. 2021 Academic Article GET IT
Times cited: 9
Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. Scientific reports. 2021 Academic Article GET IT
Times cited: 11
Newcastle Disease Virus at the Forefront of Cancer Immunotherapy. Cancers. 2020 Review GET IT
Times cited: 88
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. Gynecologic oncology. 2020 Academic Article GET IT
Times cited: 4
Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. Scientific reports. 2020 Academic Article GET IT
Times cited: 20
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 40
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 28
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature communications. 2020 Academic Article GET IT
Times cited: 131
Carcinoma-Associated Mesenchymal Stem Cells Promote Chemoresistance in Ovarian Cancer Stem Cells via PDGF Signaling. Cancers. 2020 Academic Article GET IT
Times cited: 51
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 33
BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. JCO precision oncology. 2020 Academic Article GET IT
Times cited: 18
Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. Gynecologic oncology. 2020 Academic Article GET IT
Times cited: 1
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 20
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nature genetics. 2020 Academic Article GET IT
Times cited: 100
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. European urology. 2020 Academic Article GET IT
Times cited: 56
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 152
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Journal for immunotherapy of cancer. 2020 Review GET IT
Times cited: 459
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. Gynecologic oncology. 2020 Academic Article GET IT
Times cited: 2
Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. Nature communications. 2020 Academic Article GET IT
Times cited: 19
Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation. Methods in molecular biology (Clifton, N.J.). 2020 Academic Article GET IT
Times cited: 9
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2019 Academic Article GET IT
Times cited: 14
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecologic oncology. 2019 Academic Article GET IT
Times cited: 25
PD-1 Blockade in Advanced Adrenocortical Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 91
Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum?. Molecular therapy : the journal of the American Society of Gene Therapy. 2019 Comment GET IT
Computed Tomography-Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 16
Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. Gynecologic oncology. 2019 Academic Article GET IT
Times cited: 10
Novel therapeutics: response and resistance in ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2019 Conference Paper GET IT
Times cited: 12
Preparation of single cells from tumors for single-cell RNA sequencing. Methods in enzymology. 2019 Academic Article GET IT
Times cited: 5
TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019 Academic Article GET IT
Times cited: 495
Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2019 Review GET IT
Times cited: 35
Virus, Vessel, Victory: A Novel Approach to Tumor Killing. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Comment GET IT
Times cited: 1
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecologic oncology. 2018 Academic Article GET IT
Times cited: 27
Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers. Current oncology reports. 2018 Review GET IT
Times cited: 33
IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature. 2018 Academic Article GET IT
Times cited: 205
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 18
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 79
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. 2018 GET IT
Times cited: 99
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget. 2018 Academic Article GET IT
Times cited: 21
Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study. Cancer medicine. 2018 Academic Article GET IT
Times cited: 16
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 87
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Molecular therapy : the journal of the American Society of Gene Therapy. 2018 Academic Article GET IT
Times cited: 88
Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?. Molecular therapy : the journal of the American Society of Gene Therapy. 2017 Comment GET IT
Times cited: 4
Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 49
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. 2017 GET IT
Times cited: 317
Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Science immunology. 2017 Academic Article GET IT
Times cited: 79
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature communications. 2017 Academic Article GET IT
Times cited: 93
Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors. Methods in molecular biology (Clifton, N.J.). 2017 Academic Article GET IT
Times cited: 1
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecologic oncology. 2016 Review GET IT
Times cited: 23
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine. 2016 Academic Article GET IT
Times cited: 106
Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies. Oncology (Williston Park, N.Y.). 2016 Review GET IT
Times cited: 7
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell reports. 2015 Academic Article GET IT
Times cited: 324
Immunotherapy of Melanoma. Progress in tumor research. 2015 Review GET IT
Times cited: 13
Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. Human gene therapy. 2015 Review GET IT
Times cited: 19
The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. Advances in cancer research. 2015 Review GET IT
Times cited: 40
Immune checkpoint modulation: rational design of combination strategies. Pharmacology & therapeutics. 2015 Review GET IT
Times cited: 72
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Molecular therapy oncolytics. 2014 Review GET IT
Times cited: 31
Harnessing the immune system for cancer therapy. Current opinion in oncology. 2014 Review GET IT
Times cited: 18
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science translational medicine. 2014 Academic Article GET IT
Times cited: 535
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 492
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance. Leukemia. 2013 Letter GET IT
Times cited: 13
Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation. Bone marrow transplantation. 2012 Academic Article GET IT
Times cited: 42
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future microbiology. 2012 Review GET IT
Times cited: 155
The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. Journal of translational medicine. 2011 Academic Article GET IT
Times cited: 14
Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. Journal of virology. 2011 Academic Article GET IT
Times cited: 108
Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer. Head & neck. 2010 Academic Article GET IT
Times cited: 25
Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Molecular cancer therapeutics. 2010 Academic Article GET IT
Times cited: 30
Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. The British journal of surgery. 2010 Academic Article GET IT
Times cited: 27
Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. Journal of molecular medicine (Berlin, Germany). 2010 Academic Article GET IT
Times cited: 44
Detection of free peritoneal cancer cells in gastric cancer using cancer-specific Newcastle disease virus. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2009 Academic Article GET IT
Times cited: 12
Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene therapy. 2009 Academic Article GET IT
Times cited: 67
Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Molecular therapy : the journal of the American Society of Gene Therapy. 2009 Academic Article GET IT
Times cited: 80
Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses. Equine veterinary journal. 2009 Academic Article GET IT
Times cited: 44
A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS pathogens. 2007 Academic Article GET IT
Times cited: 398
Comment on "Large-scale sequence analysis of avian influenza isolates". Science (New York, N.Y.). 2006 Comment GET IT
Times cited: 25
Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice. Journal of virology. 2006 Academic Article GET IT
Times cited: 263
Sequence analysis and receptor specificity of the hemagglutinin of a recent influenza H2N2 virus isolated from chicken in North America. Glycoconjugate journal. 2006 Academic Article GET IT
Times cited: 19
Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS pathogens. 2005 Academic Article GET IT
Times cited: 307
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. Journal of virology. 2005 Academic Article GET IT
Times cited: 337
Attenuation of equine influenza viruses through truncations of the NS1 protein. Journal of virology. 2005 Academic Article GET IT
Times cited: 202
Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. Journal of virology. 2005 Academic Article GET IT
Times cited: 152
Differential IL-10R1 expression plays a critical role in IL-10-mediated immune regulation. Journal of immunology (Baltimore, Md. : 1950). 2001 Academic Article GET IT
Times cited: 79

more ...

less ...

Background

education and training

M.D., Ph.D., Mount Sinai School of Medicine 2008
B.S., Manhattan College 2000

Contact

full name

Dmitriy Zamarin

VIVO Weill Cornell Medical College

Dmitriy Zamarin Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name